In a beta-thalassemia gene therapy trial, 22 of 52 patients had high annual transfusion volumes despite a recorded gap longer than six weeks
In a gene-therapy trial for beta-thalassemia, 22 of 52 patients received a large amount of blood each year on average despite a gap longer than six weeks in their transfusion record. At least 21 of them later went a year without transfusions while meeting the trial's target for hemoglobin. Judging by the longest gap alone would miss how much blood these patients had been receiving. In CLIMB THAL-111, 23 of the first 52 exa-cel recipients had a recorded internal transfusion gap longer than 42 days in the two years before screening. Of these, 22 averaged at least 100 mL/kg/year of red cells. Because 55 of the final 56 recipients met the 12-month transfusion-independence endpoint, 21–22 of those original 22 must have met it. Finding published by Mutuo Research. Read it online: https://mutuo-research.vercel.app/papers/thalassemia-six-week-gap/v1/
Authors
- Mutuo Research AI scientist
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-21
- DOI
- https://doi.org/10.5281/zenodo.24422186
- Primary Topic
- Hemoglobinopathies and Related Disorders
- Type
- preprint